Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07107841 · ClinicalTrials.gov registry record · NA

Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)

A NA study of Alopecia and Androgenic Alopecia, sponsored by Acorn Biolabs.

Recruiting
Registry status
NA
Development phase
60
Enrollment target
1
Study location

NCT07107841 is a NA study of Alopecia and Androgenic Alopecia that is actively recruiting participants, run by Acorn Biolabs. The registered enrollment target is 60 participants, below the 120-participant average among 13 other Alopecia trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07107841, a NA study of Alopecia and Androgenic Alopecia, is actively recruiting participants, sponsored by Acorn Biolabs.

RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

(SINGLE SITE Study) The purpose of this clinical trial is to evaluate the safety and efficacy of the use of an autologous hair follicle derived secretome for androgenous alopecia. The secretome will be injected into the scalp at baseline, and days 30, 90, 180, 270 and 365. Hair growth will be quantitatively measured for density and thickness. PROs will also be collected from participants. This study will be run at a SINGLE SITE.

Interventions

  • OTHER Autologous Hair Follicle-Derived Secretome
  • OTHER Placebo Control

Study Locations (1)

California

  • Ziering Medical - West Hollywood

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-10-16
Est. Completion 2027-09-15
Phase NA

Sponsor

Acorn Biolabs

3 total trials

What the Registry Record Tells You About NCT07107841

The ClinicalTrials.gov registry entry for NCT07107841 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 120-participant average among 13 other Alopecia trials with a reported enrollment target (50% lower). The listed sponsor is Acorn Biolabs, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Alopecia appearing as the primary indexed condition, and to 2 interventions - of which Autologous Hair Follicle-Derived Secretome is the first listed.

NCT07107841 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT07107841 about?

NCT07107841 is a clinical study titled "Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)". (SINGLE SITE Study) The purpose of this clinical trial is to evaluate the safety and efficacy of the use of an autologous hair follicle derived secretome for androgenous alopecia. The secretome will be injected into the scalp at baseline, and days 30, 90, 180, 270 and 365. Hair growth will be quant...

What is the current status of trial NCT07107841?

This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2025-10-16. Estimated completion is 2027-09-15.

What conditions does trial NCT07107841 study?

This clinical trial studies the following conditions: Alopecia, Androgenic Alopecia, Baldness.

What interventions are being tested in trial NCT07107841?

The interventions under investigation include: Autologous Hair Follicle-Derived Secretome (OTHER), Placebo Control (OTHER).

Who is sponsoring clinical trial NCT07107841?

This trial is sponsored by Acorn Biolabs, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07107841 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alopecia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.